Director-affiliated entity files intent to sell $15.9M in Liquidia Corp stock
LQDA has more than doubled off its 52-week low of $11.85 on elevated volume (4.7× avg).
Summary
A director-affiliated entity, Canaan VIII LP, plans to sell $15.9 million of Liquidia Corp stock, adding to recent insider selling activity while the stock trades near its 52-week high.
Key Events · Ownership and Investor Activity · LQDA
-
Intent to Sell Significant Stake
Canaan VIII LP, an entity with a director relationship, filed a Form 144 to sell 318,893 shares of common stock, valued at approximately $15.9 million.
-
Follows Recent Insider Selling
This proposed sale by Canaan VIII LP follows previous sales of 70,234 shares for $2.53 million by the same entity within the last three months, indicating a pattern of disposition.
-
Stock Trading Near 52-Week High
The filing occurs while Liquidia Corp's stock is trading near its 52-week high of $53.93, potentially influencing the timing of the sale.
Analysis · LQDA · Life Sciences
Canaan VIII LP, an entity with a director relationship to Liquidia Corp, has filed a Form 144 indicating its intent to sell approximately $15.9 million worth of common stock. This proposed sale represents a notable portion of the company's outstanding shares and follows previous sales by the same entity in the past three months, suggesting a continued reduction in its holdings. The stock is currently trading near its 52-week high, which could be a factor in the timing of this disposition.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LQDA was trading at $52.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $11.85 to $53.93. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.